Latham & Watkins represented Zentalis in the offering, and Cooley represented the underwriters. Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced the pricing of an underwritten offering of...
Zentalis Pharmaceuticals’ $250 Million Underwritten Offering of Common Stock
Zentalis Pharmaceuticals’ $200.2 Million Common Stock Offering
Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting...
Pfizer’s $25 Million Equity Investment in Zentalis Pharmaceuticals
Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological...
Zentalis Pharmaceuticals’ $150.4 Million Common Stock Offering
Latham & Watkins LLP represented Zentalis Pharmaceuticals in the offering. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting...